POTASSIUM PHOSPHATES INJECTION, USP 224 MG — DIN 02139545
POTASSIUM PHOSPHATE MONOBASIC : 224 MG POTASSIUM PHOSPHATE DIBASIC : 236 MG · FRESENIUS KABI CANADA LTD · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is POTASSIUM PHOSPHATES INJECTION, USP?
POTASSIUM PHOSPHATES INJECTION, USP 224 MG contains POTASSIUM PHOSPHATE MONOBASIC : 224 MG POTASSIUM PHOSPHATE DIBASIC : 236 MG. It is listed in the Health Canada Drug Product Database under DIN 02139545, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 22-Dec-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is POTASSIUM PHOSPHATES INJECTION, USP used for?
Potassium Phosphates Injection, USP is indicated as a source of phosphate, for addition to large volume intravenous fluids to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Potassium Phos Incl Comb W/0th Pot. Salts in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Potassium Phos Incl Comb W/0th Pot. Salts, across 5 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 2 | 2 | POTASSIUM PHOSPHATE MONOBASIC INJECTION, POTASSIUM PHOSPHATES | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | POTASSIUM PHOSPHATES INJECTION, USP | Sourceable in Canada |
| HOSPIRA HEALTHCARE ULC | 1 | 0 | POTASSIUM PHOSPHATE INJ 3MMP/ML | No marketed DIN |
| LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | 1 | 0 | POTASSIUM PHOSPHATES INJ | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 224 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | The format 5mL (C860529), 15mL (C860539) and 50mL (C860569) are packaged in Polypropylene plastic clear vials of 20mm of size of 10mL, 20mL and 50mL closed with 20mm gray, chlorobutyl latex free rubber stoppers and sealed with light green aluminum flip cap. The products do not contain a bacteriostatic agent or other preservatives. They are packaged 25 vials per tray. Any unused portion should be discarded. The Potassium Phosphate Injection, USP in the glass vials contains no more than 32,800 mcg/L of aluminum. The Potassium Phosphate Injection, USP in the plastic vials contains no more than 2000 mcg/L of aluminum. |
| Storage | Store at 15 °C to 30 °C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Potassium Phos Incl Comb W/0th Pot. Salts |
|---|---|
| ATC code | B05XA06 |
| AHFS class | 40:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02139545 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2139545 |
| Brand name | POTASSIUM PHOSPHATES INJECTION, USP |
| Generic / active ingredient | POTASSIUM PHOSPHATE MONOBASIC : 224 MG POTASSIUM PHOSPHATE DIBASIC : 236 MG |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
| Health Canada schedule | Ethical |
| ATC code | B05XA06 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05XA |
| Current status | MARKETED |
| Status date | 22-Dec-2015 |
| Original market date | 1984-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Potassium Phosphates Injection, USP, is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum potassium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage. Withdraw the calculated volume aseptically and transfer to appropriate intravenous fluid to provide the desired number of millimoles (mmol) of phosphorus and milliequivalents (mEq) of potassium (K+).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Potassium Phosphates Injection, USP is contraindicated in diseases where high potassium, high phosphate or low calcium levels may be encountered.
Warnings and precautions
Potassium Phosphates Injection, USP must be diluted before use. To avoid potassium or phosphate intoxication, infuse solutions containing potassium phosphates slowly. In patients with severe renal or adrenal insufficiency, administration of potassium phosphates may cause potassium intoxication, infusing high concentrations of phosphate may cause hypocalcemia, and calcium levels should be monitored. This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg per kg per day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration of TPN products and of the lock-flush solutions used in their administration.
Is Potassium Phos Incl Comb W/0th Pot. Salts in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| POTASSIUM PHOSPHATE MONOBASIC INJECTION | 176 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 00711306 |
| POTASSIUM PHOSPHATES | 236 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | 00804789 |
| POTASSIUM PHOSPHATE INJ 3MMP/ML | 224 MG | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00351539 |
| POTASSIUM PHOSPHATES INJ | 224 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | 01944878 |
2 · Same class — other molecules in ATC B05XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Sodium Chloride | 0.45% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION · 0.9% SODIUM CHLORIDE INJECTION USP · 0.9% SODIUM CHLORIDE INJECTION, USP · +23 more | 37 | 11 | Yes |
| Potassium Chloride | POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP · POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE, USP (2 MEQ/ML) · POTASSIUM CHLORIDE INJ 149MG/ML USP · +7 more | 17 | 7 | Yes |
| Sodium Bicarbonate | SODIUM BICARBONATE 5% INJ 50MG/ML USP · SODIUM BICARBONATE 5% INJ 5GM/100ML USP · SODIUM BICARBONATE INJ 4.2% · SODIUM BICARBONATE INJ 7.5% · +6 more | 18 | 5 | Yes |
| Electrolytes In Comb With Other Drugs | ADDNUTRIV · MICRO +4 REGULAR STRENGTH · MICRO PLUS 4 CONCENTRATE · MICRO PLUS 5 CONCENTRATE · +10 more | 14 | 5 | Yes |
| Calcium Gluconate | 2% CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE IN SODIUM CHLORIDE INJECTION · CALCIUM GLUCONATE INJECTION USP 10% · CALCIUM GLUCONATE INJECTION, USP 10% | 5 | 5 | Yes |
| Magnesium Sulphate | MAGNESIUM SULFATE IN WATER FOR INJECTION · MAGNESIUM SULFATE INJ 50% · MAGNESIUM SULFATE INJECTION 50% USP · MAGNESIUM SULFATE INJECTION BP · +3 more | 9 | 4 | Yes |
| Zinc Sulfate | MICRO ZN · ZINC SULFATE INJECTION, USP | 4 | 4 | Yes |
| Potassium Phos Incl Comb W/0th Pot. Salts | POTASSIUM PHOSPHATE INJ 3MMP/ML · POTASSIUM PHOSPHATE MONOBASIC INJECTION · POTASSIUM PHOSPHATES · POTASSIUM PHOSPHATES INJ · +1 more | 5 | 3 | Yes |
| Calcium Chloride | CALCIJECT INJ 100MG/ML · CALCIUM CHLORIDE INJECTION BP · CALCIUM CHLORIDE INJECTION USP · CALCIUM-35 0.25 - 10 · +1 more | 5 | 2 | Yes |
| Sodium Acetate | 16.4% SODIUM ACETATE INJECTION, USP · SODIUM ACETATE INJ 328MG/ML USP · SODIUM ACETATE INJECTION USP · SODIUM ACETATE INJECTION, USP | 5 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05XC | Vitamins | 9 | 2 |
| B05XX | Trometamol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is POTASSIUM PHOSPHATES INJECTION, USP called?
Also recorded in Canada as: monobasic potassium phosphate 0.0408 MEQ/ML Oral Solution [K-Phos] (US), monobasic potassium phosphate 0.0408 MEQ/ML Oral Solution (US), 5 ML dibasic potassium phosphate 236 MG/ML / monobasic potassium phosphate 224 MG/ML Injection (US), 15 ML dibasic potassium phosphate 236 MG/ML / monobasic potassium phosphate 224 MG/ML Injection (US), 50 ML dibasic potassium phosphate 236 MG/ML / monobasic potassium phosphate 224 MG/ML Injection (US), 15 ML dibasic potassium phosphate 300 MG/ML / monobasic potassium phosphate 175 MG/ML Injection (US), dibasic potassium phosphate 236 MG/ML / monobasic potassium phosphate 224 MG/ML Injectable Solution (US), 250 ML dibasic potassium phosphate 4.72 MG/ML / monobasic potassium phosphate 4.48 MG/ML Injection (US), 100 ML dibasic potassium phosphate 11.8 MG/ML / monobasic potassium phosphate 11.2 MG/ML Injection (US), monobasic potassium phosphate 155 MG / sodium phosphate, monobasic 350 MG Oral Tablet (US), Potassium Phosphates Injection (US), Potassium Dihydrogen Phosphate (GLOBAL), Monobasic Potassium Phosphate (US), Potassium Dihydrogen Phosphate (UK), Potassium Dihydrogen Phosphate (JP).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.